title: A phase II study of vorinostat (MK-0683) in patients with primary myelofibrosis and post-polycythemia vera myelofibrosis.
authors.affiliation: christenla@gmail.com.
authors.forename: Christen L
authors.initials: CL
authors.lastname: Andersen
authors.forename: Nana B
authors.initials: NB
authors.lastname: Mortensen
authors.forename: Tobias W
authors.initials: TW
authors.lastname: Klausen
authors.forename: Hanne
authors.initials: H
authors.lastname: Vestergaard
authors.forename: Ole W
authors.initials: OW
authors.lastname: Bjerrum
authors.forename: Hans C
authors.initials: HC
authors.lastname: Hasselbalch
mesh_terms: D006801:Humans; D006877:Hydroxamic Acids / Q000627:therapeutic use*; D011087:Polycythemia Vera / Q000150:complications*; D055728:Primary Myelofibrosis / Q000150:complications* / Q000188:drug therapy*; D016896:Treatment Outcome; D000077337:Vorinostat
chemical_list: D006877:Hydroxamic Acids; D000077337:Vorinostat
keywords: clinical response; monotherapy; post-polycythemia vera; primary myelofibrosis; vorinostat